Protein Phosphatase 1-Α Regulates AS160 Ser588 and Thr642
Total Page:16
File Type:pdf, Size:1020Kb
2606 Diabetes Volume 65, September 2016 Pragya Sharma,1 Edward B. Arias,1 and Gregory D. Cartee1,2,3 Protein Phosphatase 1-a Regulates AS160 Ser588 and Thr642 Dephosphorylation in Skeletal Muscle Diabetes 2016;65:2606–2617 | DOI: 10.2337/db15-0867 Akt substrate of 160 kDa (AS160) phosphorylation on insulin resistance is crucial for whole-body insulin re- Thr642 and Ser588 by Akt is essential for insulin’s full ef- sistance and type 2 diabetes (1). Muscle insulin resistance fect on glucose transport. However, protein phosphory- is secondary, in large part, to defective GLUT4 transloca- lation is determined by the balance of actions by kinases tion and glucose transport (2). Insulin’s stimulation of glu- fi and phosphatases, and the speci c phosphatase(s) cose transport is triggered by a complex insulin-signaling controlling AS160 dephosphorylation is (are) unknown. pathway that begins with insulin’s binding to its receptor, Accordingly, we assessed roles of highly expressed leading to receptor autophosphorylation and activation of skeletal muscle serine/threonine phosphatases (PP1, receptor tyrosine kinase (2). The insulin receptor kinase PP2A, PP2B, and PP2C) on AS160 dephosphorylation. Preliminary screening of candidate phosphatases used phosphorylates insulin receptor substrate (IRS) proteins an AS160 dephosphorylation assay. Lysates from insu- on multiple tyrosine residues, resulting in IRS protein en- lin-stimulated skeletal muscle were treated with phar- gagement with phosphatidylinositol (PI) 3-kinase (PI3K), macological phosphatase inhibitors and assessed for that in turn, phosphorylates PI 4,5-bisphosphate to create AS160 Ser588 and Thr642 dephosphorylation. AS160 de- 3,4,5-trisphosphate (PIP3). The serine/threonine kinase phosphorylation on both phosphorylation sites was un- Akt is recruited to bind PIP3 and become activated second- altered by PP2B or PP2C inhibitors. Okadaic acid (low 308 SIGNAL TRANSDUCTION ary to phosphorylation on Thr via phosphoinositide- dose inhibits PP2A; high dose inhibits PP1) delayed dependent kinase-1 (PDK1) and Ser473 via mTORC2. Akt AS160 Ser588 (both doses) and Thr642 (high dose only) phosphorylates many protein substrates, several of which dephosphorylation concomitant with greater Akt phos- have been implicated in insulin’s regulation of GLUT4 traf- phorylation (both doses). AS160 was coimmunoprecipi- fic to the cell surface membranes, including a Rab-GTPase tated with PP1-a but not with PP1-b, PP1-g1, or PP2A. activating protein known as Akt substrate of 160 kDa Recombinant inhibitor-2 protein (a selective PP1 inhibi- (AS160; also known as TBC1D4) (3–5). Akt can phosphor- tor) delayed AS160 dephosphorylation on both phos- ylate several residues on AS160. Mutation of serine or phorylation sites without altering Akt phosphorylation. threonine to alanine to prevent phosphorylation of Ser588 Furthermore, knockdown of PP1-a but not PP1-b or 642 PP1-g1 by small interfering RNA caused greater or Thr resulted in attenuation of insulin-stimulated AS160 Ser588 and Thr642 phosphorylation concomitant GLUT4 translocation, and mutation of several other Akt with unaltered Akt phosphorylation. Together, these phosphomotifs did not produce any further effects on results identified PP1-a as a regulator of AS160 Thr642 GLUT4 localization (6). Fully understanding the regulation and Ser588 dephosphorylation in skeletal muscle. of AS160 phosphorylation is essential given the crucial role that it plays in regulating insulin-stimulated glucose uptake by skeletal muscle. Skeletal muscle accounts for the largest portion of insulin- The reversible serine/threonine phosphorylation of pro- mediated whole-body glucose disposal, and skeletal muscle teins is balanced by the opposing actions of kinases and 1Muscle Biology Laboratory, School of Kinesiology, University of Michigan, Ann Received 24 June 2015 and accepted 23 May 2016. Arbor, MI © 2016 by the American Diabetes Association. Readers may use this article as 2 Department of Molecular and Integrative Physiology, University of Michigan, Ann long as the work is properly cited, the use is educational and not for profit, and Arbor, MI the work is not altered. More information is available at http://diabetesjournals 3 Institute of Gerontology, University of Michigan, Ann Arbor, MI .org/site/license. Corresponding author: Gregory D. Cartee, [email protected]. diabetes.diabetesjournals.org Sharma, Arias, and Cartee 2607 phosphatases, but for most proteins, there has been an (#ABS54), anti–PP1-b (#07–1217), anti–PP1-g1 (#07-1218), overwhelming bias to focus on serine/threonine kinases, anti–a-tubulin (#04-1117), and normal rabbit IgG polyclonal with strikingly fewer studies assessing the role of serine/ antibody control (#12-370) were purchased from EMD Milli- threonine phosphatases (7). Serine/threonine protein phos- pore. Anti-PP2Aa (#610556) was from BD Bioscience (San phatases regulate diverse aspects of growth, development, Jose, CA). PP1 Inh-2 antibody (#AF4719) was from R&D and metabolism, but relatively few protein serine/threonine Biosystems (Minneapolis, MN). Anti–PP1-a (#sc-443), anti- phosphatases control the specific dephosphorylation of a GADD34 (#sc-8327), anti-goat IgG horseradish peroxidase muchgreaternumberofphosphoprotein substrates (8). conjugate (#sc-2020), and anti-mouse IgG horseradish perox- With specific regard to AS160, many studies have analyzed idase conjugate (#sc-2060), were from Santa Cruz Biotech- the role of Akt in the insulin-stimulated phosphorylation of nology (Santa Cruz, CA). Anti-phostensin (#MB1057) was AS160 (9–13), but essentially nothing is known about the fromBioWorldTechnology,Inc.(St.LouisPark,MN).siRNA serine/threonine protein phosphatase(s) regulating AS160 against rat PP1 catalytic subunits a (#L-100270-02-0020), dephosphorylation. b (#L-100263-02-0020), or g1 (#L-096319-02-0020) Protein phosphatase 1 (PP1), PP2A, PP2B, and PP2C and RNA interference-negative control (#D-001810-10-20) are among the most abundant serine/threonine protein were purchased as SMARTpools from Dharmacon (Lafayette, phosphatases expressed by skeletal muscle (14), and we CO). Protein G magnetic beads (#10004D), RNAiMAX trans- hypothesized that AS160 dephosphorylation on Thr642 fection reagent (#13778-150), and DMEM (#11995) were and Ser588 would be regulated by one or more of these from Life Technologies (Grand Island, NY). enzymes. We evaluated the hypothesis using multiple ap- proaches, including assessment of Animal Treatment Procedures for animal care were approved by the Univer- 1. the effects of several pharmacologic serine/threonine sity of Michigan Committee on Use and Care of Animals. – protein phosphatase inhibitors on AS160 Ser588 and Male Wistar rats (aged 8 10 weeks) were from Harlan Thr642 dephosphorylation; (Indianapolis, IN). Lean (Fa/Fa) and obese (fa/fa) male – 2. the physical association of AS160 with serine/threo- Zucker rats (aged 7 8 weeks) were from Charles River nine protein phosphatases; Laboratories (Wilmington, MA). Animals were provided 3. the influence of a selective inhibitor of PP1, known as with rodent chow (Lab Diet No. 5001; PMI Nutrition In- inhibitor 2 (Inh-2) (15), on AS160 Ser588 and Thr642 ternational, Brentwood, MO) ad libitum until 1700 h the phosphorylation; and night before the experiment, when food was removed. 4. the consequences of knockdown of serine/threonine The next day at 1000 h to 1200 h, rats were anesthetized protein phosphatases by small interfering (si)RNA si- (intraperitoneal injection of sodium pentobarbital), and lencing on AS160 Ser588 and Thr642 phosphorylation. both epitrochlearis muscles were isolated and treated as described below. These experiments identified PP1-a as a serine/threonine Muscle Incubation protein phosphatase that regulates AS160 Ser588 and Thr642 Isolated epitrochlearis muscles were incubated in glass dephosphorylation in skeletal muscle. vials containing Krebs-Henseleit buffer, 0.1% BSA, RESEARCH DESIGN AND METHODS 2 mmol/L sodium pyruvate, 6 mmol/L mannitol, without (basal) or with insulin at 0.6 nmol/L (for coimmunopre- Materials cipitation [Co-IP] assays described below) or 30 nmol/L ThereagentsandapparatusforSDS-PAGEandnonfatdry (for dephosphorylation assays described below) for milk (#170-6404XTU) were from Bio-Rad (Hercules, CA). 30 min in a heated, shaking water bath at 35°C with MemCode Reversible Protein Stain (#24580) and bicincho- continuous gassing (95% O2 and 5% CO2). Immediately ninic acid (#23227) protein assay kits and tissue protein after the incubation, muscles were blotted, rapidly extraction reagent (T-PER; #78510) were from Thermo Fisher trimmed of connective tissue, and freeze-clamped with (Waltham, MA). Luminata Forte Western HRP Substrate – liquid N2 cooled aluminum tongs. Frozen muscles were (#WBLUF0100) was from EMD Millipore (Billerica, MA). stored at 280°C until subsequent homogenization and Sanguinarine chloride (#ALX-350-076) was from Enzo Life analysis. Sciences (Farmingdale, NY). FK-506 (#3631) was purchased from Tocris (Bristol, U.K.). Okadaic acid (OA; #459620) was L6 Cell Culture and Treatment purchased from Merck Millipore (Billerica, MA). Recombinant L6 myoblasts were purchased from the American Type protein phosphatase Inh-2 (#P0755) was from New England Culture Collection (Manassas, VA). L6 cells were cultured Biolabs (Ipswich, MA). Anti-phosphorylated (p)AktThr308 in DMEM, supplemented with 10% (vol/vol) FBS, 1% (#9275), anti-pAktSer473 (#9271), anti-Akt (#4691), anti- penicillin, and 100 mg/mL streptomycin in a humidified Thr642